Research Article

Ginsenoside F1 Attenuates Eosinophilic Inflammation in Chronic Rhinosinusitis by Promoting NK Cell Function

So Jeong Kim a, 1, Jinju Lee a, 1, Woo Sun Choi a, b, Hyo Jeong Kim a, b, Mi-Yeon Kim a, Sun Chang Kim c, Hun Sik Kim a, b, *

© 2021 The Korean Society of Ginseng. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Chronic rhinosinusitis (CRS) is a persistent inflammatory disorder of the paranasal sinuses and upper airways with heterogeneous clinical symptoms (e.g., congestion, stuffiness, nasal discharge, facial pain, impairment or loss of smell, cough, and fatigue) [1–3]. Inflamed tissues from patients with CRS are characterized by a range of inflammatory mediators (e.g., prostaglandins and interleukins) and cell types (e.g., eosinophils, neutrophils, mast cells, and macrophages) [2,4,5]. Eosinophilic inflammation is one of the major pathologic hallmarks of CRS, most prominently CRS with nasal polyps, and is dominant in patients with refractory CRS [6,7]. Although the etiology of CRS is multifactorial and incompletely understood, there is increasing appreciation that specific deficiencies in the innate immune system are associated with initiation and persistence of inflammation in CRS [1,2,5].

Natural killer (NK) cells are cytotoxic innate lymphoid cells that use germline-encoded receptors to rapidly recognize and lyse target cells, such as cells that have undergone neoplastic transformation or viral infection [8,9]. Moreover, NK cells produce several chemokines and cytokines (e.g., IFN-γ) that recruit and activate various immune cells (e.g., T cells and macrophages) to produce coordinated immune responses to target cells. In addition, NK cells regulate the function of other immune and inflammatory...
cells, including eosinophils, either via direct cell–cell contact or cytokine production [10–13]. NK cells regulate eosinophilic inflammation by activating and causing apoptosis of eosinophils [12]. We previously reported that NK cells help to resolve eosinophilic inflammation in the sinuses and blood in an eosinophilic CRS (ECRS) mouse model [14]. NK cells also recognize and clear eosinophils in the airway of asthmatic mice [13]. Of note, NK cells from patients with CRS have impaired effector function, and the extent of such dysfunction correlates inversely with blood and sinonasal eosinophilia [14,15]. In this regard, strategies that restore NK cell function may hold promise for the treatment of CRS, particularly ECRS. However, such a strategy has not yet been addressed, and routine first-line treatment for CRS is topical or oral glucocorticosteroids, which is often ineffective and associated with systemic side effects [16–19].

Ginsenosides are the core molecular components of ginseng, the root of Panax ginseng Meyer, and have various biomedical efficacies including anti-cancer, anti-fatigue, anti-aging, and immunomodulatory effects [20–24]. The difference in the number, position, and type of sugar moieties underlies the diverse pharmacological potential of ginsenosides [25–28]. Given their favorable safety profiles, ginsenosides are promising candidates for treating allergic and inflammatory disorders [29]; for example, ginsenosides Rh2 and Rg3 attenuate allergic airway inflammation by inhibiting NF-κB activation in a murine model of asthma and in human asthmatic airway epithelial tissues [30,31]. Moreover, ginsenosides Rd and Rg1 suppress ovalbumin-induced expression of Th2 cytokines (e.g., IL-4 and IL-13) and infiltration of eosinophils and mast cells in a murine model of allergic rhinitis [32,33]. Despite studies supporting the effectiveness of ginsenosides against allergic airway disorders, their therapeutic potential in CRS, especially ECRS, has not yet been investigated. Moreover, previous studies focused on the anti-inflammatory mechanisms of action of ginsenosides. Thus, the immune-stimulating efficacy of ginsenosides such as NK cell potentiation by G-F1 [22] in airway inflammatory disorders including CRS remains unclear. Given the causal relation between NK cell dysfunction and ECRS pathogenesis [14,15], we hypothesized that G-F1 may have therapeutic effects on the treatment of ECRS.

In this study, using a murine model of ECRS, we revealed that G-F1, a deglycosylated metabolite of G-Rg1, alleviates eosinophilic inflammation and disease pathogenesis by promoting NK cell function. This mechanism is distinct from the immunosuppressive action of glucocorticosteroids and suggests an alternative strategy for CRS treatment.

2. Materials and methods

2.1. Ginsenoside F1

Standard grade G-F1 was obtained commercially from Nanjing Zelang Medical Technology Co., Ltd. (Jiangsu, China) or was obtained by enzymatic conversion from G-Rg1 as previously described [34]. The purity of G-F1 used was > 98%.

2.2. Animals

BALB/c mice (6 to 7 weeks old) were obtained from Orient Bio Inc. (Sungnam, Korea). All mice were housed and fed under specific pathogen-free conditions. All experimental protocols were approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Science.

2.3. Murine CRS model

ECRS was induced by intranasal challenge with a mixture of 0.7 U protease from Aspergillus oryzae (Sigma-Aldrich, St. Louis, MO) and 75 μg ovalbumin (Sigma-Aldrich), diluted in sterile Dulbecco’s phosphate-buffered saline (DPBS) to a total volume of 20 μL three times a week for 5 weeks [14,35]. Control mice were intranasally challenged with DPBS. To assess the therapeutic effect of G-F1, mice were administered with an intraperitoneal injection of 50 mg/kg G-F1 or an intranasal injection of 3.5 mg/kg G-F1 three times a week during CRS modeling. Dexamethasone (Sigma-Aldrich) was used as a positive control at a dosage of 2 mg/kg intranasally as described in previous studies using murine model of ECRS and asthma [36,37]. After CRS development and treatment, nasal tissue sections were trimmed from euthanized mice and placed in 4% formaldehyde solution (Thermo Fisher Scientific, Waltham, MA).

2.4. NK cell depletion

For depletion of NK cells, mice were intraperitoneally injected with 10 μL rabbit anti-asialo ganglio-N-tetraosylceramide (anti-ASGM1; Cedarlane Laboratories Ltd., Burlington, Canada) while control mice were injected with rabbit serum (Sigma-Aldrich). Mice were injected with anti-ASGM1 or rabbit serum 1 day before an intranasal challenge with protease and ovalbumin, and injected once every 5 days until euthanasia. To evaluate NK cell depletion, splenocytes were isolated from each group of mice; stained with anti-CD3-PerCP (145-2C11; BD Biosciences, Franklin Lakes, NJ) and anti-NKp46-PE (29A1.4; BD Biosciences); and analyzed by flow cytometry.

2.5. Histological analysis

After fixation, the paraffin blocks were cut into 3 μm serial sections and stained with hematoxylin and eosin (H&E) by a pathologist in the Department of Pathology, Asan Medical Center in a blinded manner for the group assignments. Epithelial hyperplasia was scored as none (0), minimal (1), mild (2), moderate (3), or severe (4). Minimal was defined as barely detectable, mild as slightly detectable, moderate as easily detectable, and severe as very evident as previously described [38]. Maximal mucosal thickness in nasal tissue was determined at the transition zone of the olfactory and respiratory epithelia by using an image analysis system (CellSens Standard 1.7; Olympus, Tokyo, Japan). For eosinophil detection, slides were deparaffinized, rehydrated, and stained with Sirus Direct Red 80 (Sigma-Aldrich). Infiltration of eosinophils into the lamina propria was measured by counting the number of cells per high-powered field. To detect mast cells, slides of sinonasal tissue from CRS mice were deparaffinized, rehydrated, and stained with acidic toluidine blue (Sigma-Aldrich). The density of the positive area was analyzed with Image J software (NIH, Bethesda, MD) in a total of six randomly chosen fields.

2.6. Immunohistochemistry

To detect levels of hematopoietic prostaglandin D synthase (PGDS) in the sinonasal tissues of ECRS mice, slides were first incubated with peroxidase blocking solution (Bloxall blocking solution; Vector Labs, Burlingame, CA), boiled in a microwave oven in citrate buffer (pH 6; Sigma-Aldrich) diluted in distilled water for 3 min for epitope retrieval, and then washed in PBS. Thereafter, slides were incubated with a blocking solution containing 1% goat serum and 1% bovine serum albumin (BSA, Sigma-Aldrich) for 1 h at room temperature, stained with Sirius Red for identifying eosinophils, and then incubated with a primary antibody against H-PGDS
To determine production of IL-1β by macrophages in the sinonasal tissues of ECRS mice, slides were first subjected to peroxidase blocking and epitope retrieval before incubation with primary antibodies against IL-1β (1:100, 3A6; Cell Signaling Technology, Beverly, MA) and CD68 (1:100, PA-1; Bio-Rad, Hercules, CA) for 1 h, followed by Alexa Fluor 488-conjugated goat anti-mouse F(ab′)2 (1:250; Jackson ImmunoResearch, West Grove, PA) and Alexa Fluor 647-conjugated goat anti-rabbit F(ab′)2 (1:250; Jackson ImmunoResearch) for 30 min in PBS containing 1% BSA and 1% goat serum. To detect IFN-γ expression by NK cells, the processed slides were incubated with primary antibodies against IFN-γ (1:100, XMG12; Biologend, San Diego, CA) and ASGM1 (1:200; Cedarlane Labs, Ontario, Canada) for 1 h, followed by Alexa Fluor 647-conjugated goat anti-rat F(ab′)2 (1:250; Jackson ImmunoResearch) and Alexa Fluor 488-conjugated goat anti-rabbit F(ab′)2 (1:250; Jackson ImmunoResearch) for 30 min in PBS containing 1% BSA and 1% goat serum. All incubations were conducted under coverslips at room temperature, followed by three washes with PBS. Coverslips were mounted with Prolong Gold anti-fade reagent (Molecular Probes, Eugene, OR). The fluorescence signal of stained slides was imaged with an LSM 710 confocal microscope (Carl Zeiss, Switzerland) and analyzed using ImageJ software. After immunohistochemical staining, slides were assessed by light microscopy (LEICA, Wetzlar, Germany) to detect histologic abnormalities and inflammation in CRS.

2.7. Immunofluorescence

2.8. Quantitative real-time PCR (qRT-PCR)

2.9. ELISA

Primary macrophages were obtained from the intraperitoneal cavity of mice after intraperitoneal injection of 3.85% thiglycollate medium. After 3 days, the peritoneal cavity was washed using Dulbecco’s modified Eagle’s medium ( Gibco, Waltham, MA) with 10% fetal bovine serum ( Gibco), and cells recovered from the peritoneal cavity were collected. After washing, cells were seeded in a culture plate and incubated for 3 h. Macrophages were pretreated with G-F1 or dexamethasone 15 min before stimulation with LPS either for 8 h to release TNF-α, IL-6, and IL-12p40, or for 4 h followed by addition of 5 mM ATP to release IL-1β. The amount of IL-1β, TNF-α, IL-6, and IL-12p40 released into the supernatants of cultured macrophages was measured using enzyme-linked immunosorbent assays (ELISA) according to the manufacturer’s recommendation (R&D Systems, Minneapolis, MN).

2.10. Statistical analysis

All data were analyzed with GraphPad Prism software (version 5.00; GraphPad, San Diego, CA). Treatment groups were analyzed using the two-tailed Mann-Whitney U-test or Student’s t-test. P-values < 0.05 were regarded as statistically significant.

3. Results

3.1. Ginsenoside F1 alleviates eosinophilic inflammation in a murine model of CRS

We previously identified that G-F1 is the most potent of 15 ginsenosides in enhancing NK cell activity, and that it improves NK cell-mediated cancer surveillance in two distinct mouse tumor models [22]. Given the causal relation between NK cell dysfunction and ECRS pathogenesis [14,15], we tested if G-F1 could have therapeutic benefits in ECRS. To address this question, we used a previously established ECRS mouse model [14] to assess the effect of G-F1 on ECRS development. Ginsenosides often undergo metabolic transformation in the intestinal tract, such as stepwise deglycosylation of sugar moieties, which results in different and adverse pharmacological potentials [26,28,39]. Thus, G-F1 was administered to mice through local intranasal or systemic intraperitoneal injection. Treatment with G-F1 significantly and effectively alleviated eosinophilic inflammation in the sinonasal mucosa of ECRS mice following either intranasal injection of 3.5 mg/kg or intraperitoneal injection of 50 mg/kg (Fig. 1A and B). G-F1 treatment also reduced epithelial hyperplasia and maximal mucosal thickness in ECRS mice, particularly when intranasally injected (Fig. 1A and B).

The infiltration of mast cells, which produce various inflammatory mediators including PGD2 that drive eosinophilic inflammation [40,41], was reduced by G-F1 treatment (Fig. 1A and B). Collectively, these results indicate that G-F1 has a therapeutic effect on eosinophilic inflammation and disease progression in a murine model of ECRS. Because local intranasal injection (3.5 mg/kg) was more efficacious than intraperitoneal injection (50 mg/kg), we chose intranasal injection for subsequent experiments in consideration of effective dose, safety, and systemic disposition and metabolic transformation.

3.2. Ginsenoside F1 alleviates eosinophilic inflammation related to the PGD2 pathway

Next, we compared the therapeutic efficacy of G-F1 and dexamethasone, the most widely used drug for the treatment of allergic inflammatory disorders including ECRS. Mice were intranasally administered G-F1 or dexamethasone during the development of
The therapeutic efficacy of G-F1 at a dose of 3.5 mg/kg was comparable to that of dexamethasone at a dose of 2 mg/kg in terms of reducing epithelial hyperplasia, maximal mucosal thickness, and the numbers of eosinophils and mast cells infiltrating the sinonasal mucosa of ECRS mice (Fig. 2A and B). Based on this finding, we next investigated whether G-F1 or dexamethasone modulated levels of H-PGDS, an enzyme that is required for PGD2 production and is implicated in ECRS pathophysiology [42]. Immunohistochemical staining demonstrated that G-F1 significantly decreased H-PGDS protein levels, which correlated with reduced tissue eosinophilia (Fig. 2C). As expected, dexamethasone similarly reduced H-PGDS levels. These results suggest that G-F1 reduces eosinophilic inflammation by modulating the PGD2 pathway.

### 3.3. Ginsenoside F1 promotes NK cell function in sinonasal tissue of ECRS mice

To understand the mechanism of action of G-F1, we assessed the expression of selected genes related to allergic inflammation in the sinonasal tissue of ECRS mice. Using qRT-PCR, we observed that both G-F1 and dexamethasone caused a significant reduction in the mRNA expression of Th2-related IL-4 and IL-13 but not of IL-5 (Fig. 3A); this effect likely accounts for the common therapeutic efficacy of G-F1 and dexamethasone. Moreover, mRNA expression of CCL11 (eotaxin-1), but not CCL5 (RANTES), linked to eosinophil recruitment was markedly upregulated in ECRS mice, which was significantly reduced by both G-F1 and dexamethasone treatment,
Fig. 2. Comparison of the therapeutic efficacy of ginsenoside F1 (G-F1) and dexamethasone (DEX) against eosinophilic chronic rhinosinusitis (ECRS). (A) Effect of G-F1 or dexamethasone administered via intranasal (i.n.) injection on scores of epithelial hyperplasia, maximal mucosal thickness in H&E-stained tissue sections, eosinophil counts of the lamina propria in Sirius Red-stained tissue sections, and the area of toluidine blue-positive infiltrated mast cells. (B) Representative photographs of H&E (top), Sirius Red (middle), and acidic toluidine blue (bottom)-stained sections. The arrows in H&E stained sections indicate the area of leukocyte infiltration along with the changes in epithelial hyperplasia and mucosal thickness. (C) Representative immunostaining for hematopoietic prostaglandin D synthase (H-PGDS) and Sirius Red counterstaining in the sinonasal tissue from each group of mice (left). The bar chart (right) shows the H-PGDS-positive area. Scale bars = 50 μm. Data are expressed as means ± SEMs (n = 4–5 per group). *P < .05, **P < .01, and ***P < .001 by Mann–Whitney U-test.
correlating with the decrease in eosinophilic inflammation (Supplementary Fig. 1). In addition, we found a significant increase in the mRNA levels of CCL5 (RANTES) upon treatment with G-F1 but not dexamethasone. CCL5 is constitutively expressed in NK cells and is highly upregulated upon stimulation [43,44], compatible with our observation of NK cell potentiation by G-F1. Importantly, G-F1 and dexamethasone differentially regulated the mRNA expression of IL-1β and IFN-γ; dexamethasone (but not G-F1) reduced IL-1β mRNA, whereas G-F1 (but not dexamethasone) upregulated IFN-γ mRNA (Fig. 3A). G-F1 treatment also increased IL-17A mRNA levels. IL-1β is a pro-inflammatory cytokine preferentially produced by macrophages and monocytes that potentiates the production of PGE2 and Th2 cytokines by mast cells [45,46]. IFN-γ is secreted predominantly by activated lymphocytes including NK and T cells, and orchestrates Th1-mediated immune responses [47]. Immunohistochemical analysis revealed a marked increase in IL-1β staining, which was associated with the presence of CD68+ macrophages in the sinonasal mucosa of ECRS mice; dexamethasone but not G-F1 reduced the level of IL-1β staining (Fig. 3B). By contrast, G-F1 (but not dexamethasone) treatment significantly increased the level of IFN-γ staining colocalized with ASGM1+ cells, including NK cells, in the sinonasal tissue of ECRS mice (Fig. 3C). Collectively, these results suggest that the mechanism of therapeutic efficacy of G-F1 against ECRS is distinct from that of dexamethasone and likely involves promotion of NK cell function.

4. Discussion

Ginsenosides, principal active components of ginseng, have attracted considerable attention as promising therapeutic agents for the treatment of inflammatory disorders due to their immunomodulatory effects and favorable safety profiles [48,49]. Although more than 100 types of ginsenosides with differential composition of sugar moieties have been identified [50], the immuno-pharmacological effects of each ginsenoside are less clear. Numerous studies have revealed that ginsenosides exhibit either immune-suppressive or immune-stimulatory properties. This complication remains a major challenge for therapeutic development of ginsenosides. In this study, we present evidence for the first time that G-F1, a deglycosylated metabolite of Rg1, alleviates eosinophilic inflammation and disease pathogenesis by potentiating NK cell function in a murine model of ECRS. Moreover, the therapeutic mechanism of G-F1 is probably distinct from other anti-inflammatory ginsenosides (e.g., Rh2, Rg3, Rd), which are effective in allergic airway disorders (i.e., allergic rhinitis and asthma). This notion is supported by the comparison of G-F1 and dexamethasone, which has established immunosuppressive effects, in this study.

In eosinophilic inflammation in CRS is frequently associated with severe refractory disease and is thus a major therapeutic target [51,52]. In this respect, strategies that promote the resolution of eosinophilic inflammation by reducing the survival and migration of eosinophils have been actively pursued [53,54]. Using patient samples and a murine model, we previously demonstrated that there is a causal link between eosinophilic inflammation in CRS and impaired function of NK cells, which normally have an intrinsic capacity to induce eosinophil apoptosis [12,14]. In support of this finding, a recent study revealed that the function of NK cells from patients with severe refractory asthma is significantly impaired, and there is a concomitant increase in the number of target leukocytes including eosinophils [11]. In addition, NK cell function is further disabled by ex vivo exposure to dexamethasone, which likely accounts for the resistance to glucocorticosteroid therapy and the persistent inflammation seen in severe asthma [11]. Hence, selective targeting and activation of NK cells may provide an alternative therapeutic modality to treat eosinophilic inflammation in airway inflammatory disorders, particularly those resistant or refractory to glucocorticosteroid therapy. In this regard, our results showing that G-F1-mediated resolution of eosinophilia in CRS occurs via potentiation of NK cell function suggest G-F1 as an eligible and alternative candidate for ECRS treatment. We previously demonstrated that NK cell depletion after CRS development leads to persistent eosinophilic inflammation [14], an observation compatible with an important role of NK cells in the timely resolution of allergic airway inflammation [55]. Thus, we speculate that G-F1-mediated potentiation of NK cells has a therapeutic effect on ECRS even after CRS induction, which merits further investigation in various therapeutic settings. Moreover, it will be interesting to investigate whether G-F1 can alleviate other eosinophilic inflammatory disorders such as hypereosinophilic syndromes, which are associated with significant morbidity and mortality [54]. In terms of safety, doses of G-F1 up to 50 mg/kg were not associated with any systemic toxicity in ECRS mice, consistent with our previous study using a murine tumor model [22]. Moreover, owing to easy access to sinus mucosa, it was possible to administer G-F1 via the intranasal route, where it was therapeutically effective at a much lower dose (3.5 mg/kg) than via intraperitoneal delivery (50 mg/kg), further ensuring favorable efficacy at a safe dose. This dose was also comparable to the dose effective in patients with allergic rhinitis (3 mg/kg/d; the adult dose recommended by the Korea Ginseng Corporation) [56]. However, a systematic dose range-finding study
would be required to establish the therapeutic effect of G-F1 on ECRS in association with NK cells depending upon the route of administration.

A mechanistic study indicated that G-F1-mediated therapeutic effects are different from the typical glucocorticosteroids-like anti-inflammatory activity of other ginsenosides including G-Rg1 [57], a glycosylated precursor of G-F1, and were attributed to stimulation
of NK cell function. In support of a structure-dependent effects of ginsenosides on NK cell function, we previously demonstrated that G-F1 but not G-Rh1 and protopanaxatriol among the G-Rg1 metabolites significantly enhance NK cell function [22]. This substantial difference in the underlying mechanism of G-F1 was supported in this study by our comparison of the effects of G-F1 and dexamethasone. In support, the mRNA expression and protein levels of IL-1β and IFN-γ was regulated oppositely by the treatment with G-F1 and dexamethasone despite their common therapeutic effects converged at the levels of Th2 cytokines (i.e., IL-4 and IL-13) and eosinophilic inflammation. As expected, dexamethasone suppressed macrophage production of IL-1β, whereas G-F1 (but not dexamethasone) upregulated NK cell production of IFN-γ in sinonasal mucosa of ECRS mice. This differential regulation was further confirmed by assessing the effect of G-F1 or DEX on the production of various inflammatory cytokines from isolated macrophages and the disease severity of ECRS after NK cell depletion. Both IL-1β and IFN-γ contribute to the regulation of type 2 cytokine production and eosinophilic inflammation, and are implicated in CRS pathophysiology [15,35,46,47,58]. Thus, our results suggest that G-F1 and dexamethasone may target different cells or steps of the pathogenic cascade during ECRS development, eventually leading to common therapeutic outcomes. However, the involvement of other cytokines, mediators, and cells including mast cells affected by G-F1 or dexamethasone cannot be excluded, which deserves further investigation.

In sum, this study demonstrates that G-F1 has a previously unrecognized potential to promote the resolution of eosinophilic inflammation in CRS by promoting NK cell effector function. Moreover, the finding that G-F1 modulates the function of NK cells but not macrophages, and a comparison of these effects with dexamethasone, provides new insight into potential therapeutic mechanisms that could underlie ECRS treatment. Given the appreciation that G-F1 is pharmacologically active in the human systemic circulation [59], our findings may provide a rationale for developing G-F1 as a candidate for the treatment of refractory inflammatory disorders driven by eosinophils.
Fig. 5. NK cell depletion nullified the therapeutic efficacy of ginsenoside F1 (G-F1) but not dexamethasone (DEX). (A) Effect of G-F1 or dexamethasone after NK cell depletion with anti-ASGM1 on scores of epithelial hyperplasia, maximal mucosal thickness in H&E-stained tissue sections, eosinophil counts of the lamina propria in Sirius Red-stained tissue sections, and the area of toluidine blue-positive infiltrated mast cells. (B) Representative photographs of H&E (top)-, Sirius Red (middle)-, and acidic toluidine blue (bottom)-stained sections from chronic rhinosinusitis mice treated with vehicle (upper) or anti-ASGM1 (lower). The arrows in H&E stained sections indicate the area of leukocyte infiltration along with the changes in epithelial hyperplasia and mucosal thickness. Scale bars = 50 μm. Data are expressed as means ± SEMs (n = 5–6 per group). *P < .05, **P < .01, and ***P < .001 by Mann–Whitney U-test.
Supplementary data to this article can be found online at https://doi.org/10.1007/jgjr.2021.03.007.

References

[1] Lee S, Lane AP. Chronic rhinosinusitis as a multifactorial inflammatory disorder. Current Infectious Disease Reports 2011;13(2):159–68.
[2] Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyps. Annu Rev Pathol 2017;12(1):331–57.
[3] Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Immunopathology of chronic rhinosinusitis. Allergology International 2012;61(1):27-32.
[4] Kato A. Immunopathology of chronic rhinosinusitis. Allergology International 2015;64(2):121–23.
[5] Lopez-Caconch M, Mullot J, Pujol L. Clinical and immunological markers of difficulty-to-treat severe chronic rhinosinusitis. Curr Allergy Asthma Rep 2015;15(5):19.
[6] Shah SA, Ishihara H, Takeuchi K. Pathogenesis of eosinophilic chronic rhinosinusitis. Journal of Inflammation 2016;13:11.
[7] Vives E, Tomasello E, Baratin M, Walter T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008;9(5):503–10.
[8] Long EO, Sik Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013;31:227–58.
[9] Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human natural killer cells: from patients with chronic rhinosinusitis have impaired effector functions. J Immunol 2013;189(5):2717–27.
[10] Kim JH, Choi GE, Lee B-J, Kwon SW, Lee S-H, Kim HS, et al. Natural killer cells regulate eosinophilic inflammation in chronic rhinosinusitis. Scientific Reports 2016;6:27615.
[11] Kim JH, Kim GE, Cho GS, Kwon HJ, Jou CH, Kim HS, et al. Natural killer cells from patients with chronic rhinosinusitis have impaired effector functions. J Immunol 2013;189(5):2717–27.
[12] Fujieda S, Imoto Y, Kato Y, Ninomiya T, Tokunaga T, Tsutsuiuchi T, et al. Eosinophilic chronic rhinosinusitis. Allergol Int 2019;68(4):403–12.
[13] Sjärne P, Olsson P, Alexius M. Use of mometason furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2009;135(3):296–302.
[14] Walsh LJ, Lewis SA, Wong CA, Cooper S, Obarne J, Cawte SA, et al. The impact of corticosteroids on tissue mineral density and vertebral fracture. Am J Respir Crit Care Med 2002;166(5):691–5.
[15] Jung JH, Kang IG, Kim DY, Hwang YJ, Kim ST. The effect of Korean red ginseng on allergic inflammation in a murine model of allergic rhinitis. Journal of Ginseng Research 2013;37(2):167–75.
[16] Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014;38(3):161–6.
[17] Qi LW, Wang CZ, Yuan CS. American ginseng: potential structure-function mechanism of Panax ginseng. Biomolecules 2020;10(3):444.
[18] Kim JH, Yi YS, Kim MY, Cho JY. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res 2017;41(4):435–43.
[19] Kim JH, Yi YS, Kim MY, Cho JY. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res 2017;41(4):435–43.
[20] Kwon H-J, Lee H, Choi G-E, Kwon SJ, Song AV, Kim SJ, et al. Ginsenoside F1 promotes cytotoxic activity of NK cells via insulin-like growth factor-1-dependent mechanism. Frontiers in Immunology 2018;9:2785.
[21] Jia L, Zhao Y. Current evaluation of the millennium phytomedicine–ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Current Medicinal Chemistry 2009;16(19):2475–84.
[22] Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell activation in a murine model of asthma. J Allergy Clin Immunol 2013;132(5):1268–75.
[23] Lee KS, Yi YS, Kim MY, Cho JY. Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res 2017;41(4):435–43.
[24] Kwon H-J, Lee H, Choi G-E, Kwon SJ, Song AY, Kim SJ, et al. Ginsenoside F1 inhibits the TSLP proinflammatory response in human primary respiratory epithelial cells. Frontiers in Immunology 2018;9:2785.
[25] Oh HA, Sze YJ, Jeong HJ, Kim HM, Ginsenoside Rg1 inhibits the TSLP production in allergic rhinitis mice. Immunopharmacol Immunotoxicol 2013;35(4):678–86.
[26] Kim JK, Kuk CH, Yoon MH, Kim SC, Im WT. Bioconversion of major ginsenosides Rg1 to minor ginsenoside F1 using novel recombinant human ginsenoside hydrolzing glycosidase cloned from Sanguinibacter keddii and enzyme characterization. Journal of Biotechnology 2012;161(3):294–301.
[27] Choi GE, Yoon SY, Kim JY, Kang DY, Jung YJ, Kim HS. Autohyphy deficiency in myeloid cells exacerbates eosinophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol 2018;141(3):938–950 e12.
[28] Khalmuratova R, Lee M, Park JW, Shin HW. Evaluation of neo-osteogenesis in chronic eosinophilic rhinosinusitis using a nasal polyp murine model. Allergy Asthma Immunol Res 2020;12(4):206–21.
[29] Zappa CD, Soto A, Granja-Galeano G, Feno Y, Fernandez N, Davio CA, et al. Azelastine potentiates antinflammatory dexamethasone effect on a murine asthma model. Pharmacol Res Perspect 2019;7(6):e00531.
[30] Lindsay R, Slaughter T, Britton-Webb J, Mog SR, Conran R, Tadors M, et al. Development of a murine model of chronic rhinosinusitis. Otolaryngol Head Neck Surg 2006;135(4):724–30. discussion 31–2.
[31] Qi LW, Wang CZ, Yuan CS. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol 2010;80(7):947–54.
[32] Pawankar R, Lee KH, Nonaka M, Takizawa R. Role of mast cells and basophils in chronic rhinosinusitis. Clin Exp Allergy 2016;46(8):998–1006.
[33] Di Lorenzo G, Drago A, Esposito Pelletrini M, Candores G, Colombo A, Gervasi F, et al. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyps. Int Arch Allergy Immunol 2005;137(2):146–75.
[34] Okano M, Fujiiwara T, Yamamoto M, Sugata Y, Matsumoto R, Fukushima K, et al. Role of prostaglandin D2 and E2 terminal synthases in chronic rhinosinusitis. Clin Exp Allergy 2006;36(8):1026–38.
[35] Kang S, Son P, Hong Y, Neuner E, Teobon PJ. JNK MAPK pathway regulates constitutive mechanism of Panax ginseng. Biomolecules 2020;10(3):444.
[36] Jia L, Zhao Y. Current evaluation of the millennium phytomedicine–ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Current Medicinal Chemistry 2009;16(19):2475–84.
[37] Ashraf M, Murakami M, Kudo J. Cross-linking of the high-affinity IgE receptor induces the expression of cyclo-oxygenase 2 and attendant prostaglandin
generation requiring interleukin 10 and interleukin 1 beta in mouse cultured mast cells. Biochem J 1996;320(Pt 3):965–73.

[46] Hultner L, Kolsch S, Stassen M, Kaspers U, Kremer JP, Mailhammer R, et al. In activated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. J Immunol 2000;164(11):5556–63.

[47] Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Frontiers in Immunology 2018;9:847.

[48] Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58(11):1685–93.

[49] Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Frontiers in Immunology 2018;9:847.

[50] Liu CX, Xiao PG. Recent advances on ginseng research in China. J Ethnopharmacol 1992;36(1):27–38.

[51] Zhang N, Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2014;28(3):192–8.

[52] Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125(6):1344–13453 e2.

[53] Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T, et al. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 2012;130(3):563–71.

[54] Haworth O, Cernadas M, Levy BD. NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J Immunol 2011;180(11):6129–35.

[55] Jung JH, Kang TK, Oh JH, Jeong JU, Ko KP, Kim ST. The effect of Korean red ginseng on symptoms and inflammation in patients with allergic rhinitis. Ear Nose Throat J 2020. 145561320907172:online ahead of print.

[56] Du J, Cheng B, Zhu X, Ling C. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects. J Immunol 2011;187(2):942–50.

[57] Jyonouchi H, Sun S, Le H, Rimell FL. Evidence of dysregulated cytokine production by sinus lavage and peripheral blood mononuclear cells in patients with treatment-resistant chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg 2001;127(12):1488–94.

[58] Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Disposit 2003;31:1065–71.